Overview

Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism

Status:
Not yet recruiting
Trial end date:
2024-12-16
Target enrollment:
Participant gender:
Summary
To study the efficacy and safety of finerenone vs. spironolactone in patients with primary aldosteronism
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Treatments:
Spironolactone